For research use only. Not for therapeutic Use.
STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research[1].
STX-478 (0-10,000 nM; 1 h) demonstrates selectivity for MCF10A cells harboring the H1047R kinase-domain mutation[1].
STX-478 (30, 100 mg/kg; p.o.; single daily for 28 days) dose-dependently reduces tumor volume in a CAL-33 xenograft mice model[1].
| Catalog Number | I040765 |
| CAS Number | 2883540-92-7 |
| Synonyms | 1-(2-aminopyrimidin-5-yl)-3-[(1R)-1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethyl]urea |
| Molecular Formula | C16H12F5N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H12F5N5O2/c1-6-9-2-7(17)3-10(18)12(9)28-11(6)13(16(19,20)21)26-15(27)25-8-4-23-14(22)24-5-8/h2-5,13H,1H3,(H2,22,23,24)(H2,25,26,27)/t13-/m1/s1 |
| InChIKey | LGPNQALKGDDVBD-CYBMUJFWSA-N |
| SMILES | CC1=C(OC2=C1C=C(C=C2F)F)C(C(F)(F)F)NC(=O)NC3=CN=C(N=C3)N |
| Reference | [1]. JR David St Jean, et al. Urea derivatives which can be used to treat cancer. Patent WO2022265993A1. |
